Trelegy Ellipta 200 ug/1

Trelegy Ellipta 200 ug/1 is a combination inhaler containing fluticasone furoate, umeclidinium bromide, and vilanterol trifenatate. It is designed for respiratory conditions, offering a convenient once-daily treatment option. This powder inhaler is manufactured by GlaxoSmithKline LLC in the USA.

Trelegy Ellipta 200 ug/1 is primarily used for the maintenance treatment of chronic obstructive pulmonary disease (COPD). It combines an inhaled corticosteroid, a long-acting muscarinic antagonist, and a long-acting beta-agonist to help manage symptoms. This medication is often prescribed for individuals who require a combination of these active ingredients to control their respiratory condition effectively.

Common effects of Trelegy Ellipta 200 ug/1 may include throat irritation, headache, and a dry mouth. Some users might experience a taste disturbance or cough. These effects are generally mild and temporary, but if they persist or worsen, it is advisable to consult a healthcare professional.

Trelegy Ellipta 200 ug/1 should be used as directed by a healthcare provider. It is important to follow the prescribed dosage and administration instructions. Patients with a history of asthma or other respiratory conditions should use this medication with caution. Always store the inhaler in a clean, dry place and keep it out of reach of children.

Trelegy Ellipta 200 ug/1 may interact with other medications, including beta-blockers, diuretics, and certain antidepressants. It is important to inform your healthcare provider about all medications you are taking to avoid potential interactions. Additionally, alcohol consumption should be moderated while using this inhaler.